title: Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: update on methods to reduce false tests.
abstract: We report on our 6-year experience of expanded newborn screening by tandem mass spectrometry in Tuscany (Italy), the first Italian Region to screen all newborns for more than 40 inborn errors of metabolism: organization, diseases observed and updates on methods to reduce false-positive and false-negative tests are described. Blood collection is recommended between 48 and 72 h of life. Blood spots are sent daily by courier to laboratory. When a positive result occurs, two subsequent procedures are followed: for disorders with possible acute metabolic decompensation, the baby is immediately recalled and clinical examinations and confirmatory tests are performed; for the other disorders, the nursery provides for a second blood spot. If the test is positive, clinical examinations and confirmatory tests are performed. In both cases, if confirmatory tests are positive, a treatment and a follow-up programme are started. Up to now, spots from 160 000 infants have been analysed and 80 affected patients have been identified (disorders of amino acids, organic acids and fatty acids metabolism). We describe adjustments to cut-off values, the introduction of a second-tier test for propionic acidaemia and for methylmalonic aciduria, the inclusion of succinylacetone in the panel of metabolites, and protocols for premature infants and for newborns on parenteral nutrition or transfused. These changes resulted in a reduction in recalls from 1.37% to 0.32% and consequently of working time and parental stress. Avoiding false-negatives by using more specific markers and minimizing the false-positive rate with second-tier testing is important for a successful newborn screening programme.
authors.affiliation: Meyer Children's Hospital, Metabolic Unit, Florence, Italy. g.lamarca@meyer.it
authors.forename: G
authors.initials: G
authors.lastname: la Marca
authors.forename: S
authors.initials: S
authors.lastname: Malvagia
authors.forename: B
authors.initials: B
authors.lastname: Casetta
authors.forename: E
authors.initials: E
authors.lastname: Pasquini
authors.forename: M A
authors.initials: MA
authors.lastname: Donati
authors.forename: E
authors.initials: E
authors.lastname: Zammarchi
mesh_terms: D015415:Biomarkers / Q000097:blood*; D002853:Chromatography, Liquid; D005188:False Negative Reactions; D005189:False Positive Reactions; D006801:Humans; D007231:Infant, Newborn; D007558:Italy; D008661:Metabolism, Inborn Errors / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D015997:Neonatal Screening / Q000379:methods*; D011237:Predictive Value of Tests; D016730:Program Development; D015397:Program Evaluation; D015203:Reproducibility of Results; D013048:Specimen Handling; D053719:Tandem Mass Spectrometry
chemical_list: D015415:Biomarkers